Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells 42,533 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 42,533 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $0.92, for a total value of $39,130.36. Following the transaction, the insider directly owned 5,125,770 shares in the company, valued at approximately $4,715,708.40. This represents a 0.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Monday, November 24th, Bioventures 2014 L.P. Mpm sold 88,802 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $87,025.96.
• On Friday, November 21st, Bioventures 2014 L.P. Mpm sold 64,331 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.83, for a total value of $53,394.73.
• On Thursday, November 20th, Bioventures 2014 L.P. Mpm sold 41,152 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total transaction of $36,625.28.
• On Wednesday, November 19th, Bioventures 2014 L.P. Mpm sold 66,324 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $62,344.56.
• On Tuesday, November 18th, Bioventures 2014 L.P. Mpm sold 52,627 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total transaction of $48,943.11.
• On Monday, November 17th, Bioventures 2014 L.P. Mpm sold 57,061 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.95, for a total transaction of $54,207.95.
• On Friday, November 14th, Bioventures 2014 L.P. Mpm sold 61,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total transaction of $57,325.20.
• On Thursday, November 13th, Bioventures 2014 L.P. Mpm sold 90,951 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $89,131.98.
• On Wednesday, November 12th, Bioventures 2014 L.P. Mpm sold 40,669 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total value of $44,329.21.
• On Tuesday, November 11th, Bioventures 2014 L.P. Mpm sold 55,810 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total value of $63,623.40.

Werewolf Therapeutics Stock Performance

NASDAQ:HOWL traded down $0.07 during mid-day trading on Tuesday, hitting $0.91. 461,162 shares of the company’s stock traded hands, compared to its average volume of 505,004. The firm has a market capitalization of $44.19 million, a price-to-earnings ratio of -0.56 and a beta of 0.73. The firm has a 50 day moving average of $1.52 and a two-hundred day moving average of $1.34. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 12 month low of $0.60 and a 12 month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

A number of large investors have recently bought and sold shares of HOWL. Quadrature Capital Ltd bought a new position in shares of Werewolf Therapeutics during the second quarter valued at $28,000. Qube Research & Technologies Ltd bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth about $48,000. Nuveen LLC acquired a new stake in shares of Werewolf Therapeutics during the 1st quarter worth about $71,000. AQR Capital Management LLC bought a new position in Werewolf Therapeutics during the 1st quarter valued at about $79,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Werewolf Therapeutics during the 2nd quarter valued at about $92,000. 64.84% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Zacks Research cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday. Citigroup restated a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Bank of America reduced their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Finally, JMP Securities lowered their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 21st. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.